TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.
Adequate balance sheet with limited growth.
Share Price & News
How has TELA Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TELA's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how TELA performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how TELA performed against the US Market.
Price Volatility Vs. Market
How volatile is TELA Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StTELA Bio, Inc. (NASDAQ:TELA) Analysts Just Slashed This Year's Revenue Estimates By 32%
4 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most TELA Bio, Inc. (NASDAQ:TELA) Stock?
Is TELA Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TELA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TELA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TELA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: TELA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TELA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TELA is overvalued based on its PB Ratio (6.2x) compared to the US Medical Equipment industry average (3.7x).
How is TELA Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TELA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TELA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TELA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TELA's revenue (42.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: TELA's revenue (42.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TELA's Return on Equity is forecast to be high in 3 years time
How has TELA Bio performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TELA is currently unprofitable.
Growing Profit Margin: TELA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TELA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).
Return on Equity
High ROE: TELA has a negative Return on Equity (-97.74%), as it is currently unprofitable.
How is TELA Bio's financial position?
Financial Position Analysis
Short Term Liabilities: TELA's short term assets ($55.3M) exceed its short term liabilities ($4.2M).
Long Term Liabilities: TELA's short term assets ($55.3M) exceed its long term liabilities ($30.4M).
Debt to Equity History and Analysis
Debt Level: TELA's debt to equity ratio (124.1%) is considered high.
Reducing Debt: Insufficient data to determine if TELA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TELA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TELA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 22.5% each year.
What is TELA Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TELA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TELA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TELA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TELA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TELA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Antony Koblish (54yo)
Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20 ...
CEO Compensation Analysis
Compensation vs Market: Antony's total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.
|Co-Founder & Chief Medical Officer||7.58yrs||US$907.67k||0.55% $1.0m|
|Chief Technology Officer||3.58yrs||US$844.92k||0.073% $138.8k|
|Chief Financial Officer||1.5yrs||no data||0.025% $48.5k|
|Vice President of Operations||no data||no data||no data|
|Vice President of Corporate Development & Investor Relations||1.5yrs||no data||no data|
|Vice President of Sales||no data||no data||no data|
|Chief of Strategy||0.50yr||no data||no data|
|Chief Commercial Officer||0.50yr||no data||no data|
|VP of Finance||no data||no data||no data|
Experienced Management: TELA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|Independent Director||8.5yrs||US$43.40k||no data|
|Independent Director||0.67yr||US$63.17k||no data|
|Independent Chairman||0.25yr||no data||no data|
|Independent Director||0.25yr||no data||no data|
|Independent Director||1.67yrs||US$78.72k||no data|
|Independent Director||7.58yrs||US$66.79k||no data|
Experienced Board: TELA's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TELA only recently listed within the past 12 months.
TELA Bio, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: TELA Bio, Inc.
- Ticker: TELA
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$190.324m
- Shares outstanding: 14.41m
- Website: https://www.telabio.com
Number of Employees
- TELA Bio, Inc.
- 1 Great Valley Parkway
- Suite 24
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TELA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2019|
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/09 00:04|
|End of Day Share Price||2020/07/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.